Nanobiotix S.A. (NBTX)
| Market Cap | 254.87M |
| Revenue (ttm) | 7.41M |
| Net Income (ttm) | -64.60M |
| Shares Out | 47.11M |
| EPS (ttm) | -1.79 |
| PE Ratio | n/a |
| Forward PE | 48.31 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,558 |
| Open | 5.55 |
| Previous Close | 5.50 |
| Day's Range | 5.20 - 5.69 |
| 52-Week Range | 1.75 - 11.00 |
| Beta | 1.25 |
| Analysts | Buy |
| Price Target | 11.00 (+103.33%) |
| Earnings Date | Apr 24, 2024 |
About NBTX
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Grea... [Read more]
Financial Performance
In 2022, Nanobiotix's revenue was 4.78 million, an increase of 80.43% compared to the previous year's 2.65 million. Losses were -57.04 million, 21.4% more than in 2021.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to one analyst, the rating for NBTX stock is "Buy" and the 12-month stock price forecast is $11.0.
News
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024
Conference call and webcast scheduled for Thursday, April 25, 2024, at 8:00 am EDT / 2:00 pm. CEST Conference call and webcast scheduled for Thursday, April 25, 2024, at 8:00 am EDT / 2:00 pm. CEST
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
PARIS and CAMBRIDGE, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based appr...
Nanobiotix to Present at Upcoming Investor Conferences in March
PARIS and CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based appro...
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
PARIS and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approa...
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study
PARIS and CAMBRIDGE, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based appro...
NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update
$2.5 billion global licensing, co-development, and commercialization agreement expands worldwide potential of novel radioenhancer NBTXR3 16.9 months median progression free survival (mPFS) and 23.1 mo...
NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023
Conference call and webcast scheduled for Tuesday, November 14, 2023, at 2:00 pm. CET / 8:00 am ET Conference call and webcast scheduled for Tuesday, November 14, 2023, at 2:00 pm. CET / 8:00 am ET
NANOBIOTIX Announces Closing of Global Offering
PARIS and CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics...
NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6M
PARIS and CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics...
NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M
PARIS and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics...
NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant
PARIS and CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics...
NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023
Strategic Collaborator-presented Phase 1 Pancreatic Cancer Data An ongoing Phase 1, collaborator-led study of NBTXR3 in locally advanced pancreatic cancer (LAPC) established a favorable safety profile...
Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 Months
Results presented in an oral presentation by Professor Christophe Le Tourneau, MD, PhD, of Institut Curie, and highlighted in two scientific sessions at the 65th Annual Meeting of the American Society...
NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology
Conference call and live webcast Thursday, October 5th, 2023, at 8:00 AM EDT/2:00pm CEST Conference call and live webcast Thursday, October 5th, 2023, at 8:00 AM EDT/2:00pm CEST
NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer
Data presented at the 2023 Special Meeting on Pancreatic Cancer of the American Association for Cancer Research
NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3 Upfront payment and first equity t...
Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023
Conference Call and Webcast to be Held at 8:00 AM EDT / 2:00 PM CEST on September 27, 2023 Conference Call and Webcast to be Held at 8:00 AM EDT / 2:00 PM CEST on September 27, 2023
NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer
PARIS and CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “Company”), a late-clinical stage biotechnology company pioneering physics-based approach...
NANOBIOTIX to Present at the H.C. Wainwright 25th Annual Global Investment Conference
PARIS and CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approa...
NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3
PARIS and CAMBRIDGE, Mass., Aug. 15, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approa...
NANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023
PARIS and CAMBRIDGE, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approa...
NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers
PARIS and CAMBRIDGE, Mass., July 19, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO — NASDAQ: NBTX – the “Company”), a late-clinical stage biotechnology company pioneering physics-based approache...
Nanobiotix ADRs Jump Over 50% After Agreement With J&J's Janssen Pharmaceutical
American depositary receipts of Nanobiotix jumped over 50% in early trading on Monday after signing an agreement with J&J's Janssen Pharmaceutical to work on co-developing a drug to treat head and nec...
Nanobiotix's stock soars after entering licensing, development deal with J&J's Janssen Pharmaceutica
Shares of Nanobiotix SA NBTX, +1.57% shot up 52.1% toward a 17-month high in premarket trading Monday, after the France-based biotechnology company announced a global licensing and co-development agre...
NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3
PARIS and CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approa...